Overview

• The Series D includes existing investors CVS Health Ventures, Foresite Capital and a16z Bio + Health, with new participation from Morgan Health, Humana, Texas Oncology and Memorial Hermann Health System.
• The raise brings total capital to $275 million as the company reports profitability, stewardship of more than $5 billion in oncology spend and access extended to roughly 8 million people through Medicare, commercial and employer contracts.
• Thyme Care’s model pairs a technology-enabled care team with payer–provider alignment and collaborates with more than 1,000 oncologists to streamline coordination and reduce administrative burden.
• Company-reported results include about 90% of members feeling more supported, 72% ePRO participation, 40% fewer ER visits and 19% fewer hospital admissions among ePRO completers, plus nearly 2,000 staff hours saved at one partner practice.
• The company plans to deepen AI capabilities and expand partnerships, and some outlets report the new round places its valuation above $1 billion, which has not been uniformly confirmed.